Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas

[1]  F. Motoi,et al.  Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection , 2022, Journal of hepato-biliary-pancreatic sciences.

[2]  Angelika M. R. Kestler,et al.  Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  G. Webersinke,et al.  Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer , 2022, Frontiers in Oncology.

[4]  M. Senthil,et al.  Circulating Tumor DNA is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis , 2022, Annals of Surgical Oncology.

[5]  W. Hwang,et al.  Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. , 2022, JCO precision oncology.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  P. Laurent-Puig,et al.  Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials , 2021, British Journal of Cancer.

[8]  F. Motoi,et al.  Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases , 2021, Annals of Surgical Oncology.

[9]  Ann M. Miller,et al.  Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies , 2020, Annals of Surgical Oncology.

[10]  L. Buscail,et al.  Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer , 2020, Nature Reviews Gastroenterology & Hepatology.

[11]  W. Roth,et al.  Liquid Biopsy im kolorektalen Karzinom , 2019, Der Pathologe.

[12]  N. Hartmann,et al.  [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics]. , 2019, Der Pathologe.

[13]  J. Nuyttens,et al.  Postoperative surveillance of pancreatic cancer patients. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  J. Cameron,et al.  Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[16]  R. Kurzrock,et al.  Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival , 2018, Annals of Surgical Oncology.

[17]  E. Sabo,et al.  Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. , 2018, The oncologist.

[18]  Xinhui Fang,et al.  Liquid biopsy in colorectal cancer , 2018 .

[19]  B. Dörken,et al.  CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Cameron,et al.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.

[21]  S. Horiguchi,et al.  Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[22]  E. Hiyama,et al.  Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer , 2016, British Journal of Cancer.

[23]  A. Parikh,et al.  Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence? , 2016, Journal of the American College of Surgeons.

[24]  B. Erickson,et al.  Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. , 2016, Surgery.

[25]  S. Stein,et al.  Circulating Cell-Free Tumour DNA in the Management of Cancer , 2015, International journal of molecular sciences.

[26]  M. Kanda,et al.  Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. , 2014, Hepato-gastroenterology.

[27]  K. Jung,et al.  Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[28]  Rochelle L. Garcia,et al.  Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. , 2005, American journal of obstetrics and gynecology.

[29]  S. Kitano,et al.  Factors Predicting Recurrence After Resection of Pancreatic Ductal Carcinoma , 2005, Pancreas.

[30]  M. Stroun,et al.  Isolation and characterization of DNA from the plasma of cancer patients. , 1987, European journal of cancer & clinical oncology.

[31]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.